U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 107311 - 107320 of 107352 results

Concept
Status:
Investigational
Source:
INN:REVOSIMELINE [INN]
Source URL:

Class:
CONCEPT

Concept
Status:
Investigational
Source:
INN:iosefamic acid
Source URL:

Class:
CONCEPT

Iosefamic Acid is triiodoisophthalamic acid derivative patented by Mallinckrodt Chemical Works as x-ray contrast agent for imaging in the biliary and urinary systems and in vasography.
Concept
Status:
Investigational
Source:
INN:tomelukast
Source URL:

Class:
CONCEPT


Conditions:

Tomelukast (previously known as LY171883), an orally active antagonist of the CysLT1 receptor (leukotriene D4), which was investigated to treat asthma, but this study was discontinued because of adverse gastrointestinal effect.
Concept
Status:
Investigational
Source:
NCT00570063: Phase 2 Schizophrenia
(2007)
Source URL:

Class:
CONCEPT



PF-2545920 is an orally-active phosphodiesterase 10A (PDE10A) inhibitor originated by Pfizer, for the treatment of Huntington's disease. PF-2545920 was originally developed by Pfizer for the treatment of schizophrenia. But later clinical studies for Schizophrenia were discontinued. PF-2545920 is a potent and selective PDE10A inhibitor with IC50 of 0.37 nM, with >1000-fold selectivity over the PDE. PF-2545920 is active in a range of antipsychotic models, antagonizing apomorphine-induced climbing in mice, inhibiting conditioned avoidance responding in both rats and mice, and blocking N-methyl-D-aspartate antagonist-induced deficits in prepulse inhibition of acoustic startle response in rats, while improving baseline sensory gating in mice.
Concept
Status:
Investigational
Source:
NCT01497119: Phase 2 Dermatitis, Atopic
(2011)
Source URL:

Class:
CONCEPT


JNJ-39758979 is a histamine H4 receptor antagonist which clinical development for asthma and atopic dermatitis was halted during phase II because of the observation of idiosyncratic drug-induced agranulocytosis in two subjects.
Concept
Status:
Investigational
Source:
NCT00383214: Phase 3 Systemic Lupus Erythematosus
(2005)
Source URL:

Class:
CONCEPT

Concept
Status:
Investigational
Source:
INN:BAZLITORAN [INN]
Source URL:

Class:
CONCEPT

Concept
Status:
Investigational
Source:
INN:VOTRISIRAN [INN]
Source URL:

Class:
CONCEPT

Concept
Status:
Investigational
Source:
INN:SUVODIRSEN [INN]
Source URL:

Class:
CONCEPT

Concept
Status:
Investigational
Source:
INN:BRIVOLIGIDE [INN]
Source URL:

Class:
CONCEPT

Showing 107311 - 107320 of 107352 results